Age-associated decrease in global DNA methylation in patients with major depression

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 2105-2114

  Tseng, Ping Tao ^a,b   Lin, Pao Yen ^a,c   Lee, Yu ^a   Hung, Chi Fa ^a   Lung, For Wey ^d,e   Chen, Cheng Sheng ^f,g   Chong, Mian Yoon ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Tsyr Huey Mental Hospital   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

5 hydroxymethylcytosine; 5 methylcytosine; Antidepressant; Epigenetic; Gene modification; Mood disorder

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CHLORPROMAZINE; DNA; IMIPRAMINE;

ADULT; AGE; AGED; AGING; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PSYCHOLOGIC ASSESSMENT; RECURRENT DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84910090768     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S71997     Document Type: Article

References (60)

1. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-1562.
2. Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol. 2012;233(1):102-111.
3. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7(8):847-854.
4. Perroud N, Paoloni-Giacobino A, Prada P, et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: a link with the severity and type of trauma. Transl Psychiatry. 2011;1:e59.
5. Jiao J, Opal MD, Dulawa SC. Gestational environment programs adult depression-like behavior through methylation of the calcitonin gene-related peptide gene. Mol Psychiatry. 2013;18(12):1273-1280.
6. Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med. 2011;41(5):997-1007.
7. Rotter A, Asemann R, Decker A, Kornhuber J, Biermann T. Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J Affect Disord. 2011;131(1-3):186-192.
8. Fuchikami M, Morinobu S, Segawa M, et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One. 2011;6(8):e23881.
9. Zill P, Baghai TC, Schüle C, et al. DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. PLoS One. 2012;7(7):e40479.
10. Sun HS, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology. 2013;38(1):124-137.
11. Booij L, Wang D, Levesque ML, Tremblay RE, Szyf M. Looking beyond the DNA sequence: the relevance of DNA methylation processes for the stress-diathesis model of depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120251.
12. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9(16):2395-2402.
13. Wu H, Coskun V, Tao J, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science. 2010;329(5990):444-448.
14. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.
15. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004;32(14):4100-4108.
16. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem. 2003;278(6):4035-4040.
17. Free A, Wakefield RI, Smith BO, Dryden DT, Barlow PN, Bird AP. DNA recognition by the methyl-CpG binding domain of MeCP2. J Biol Chem. 2001;276(5):3353-3360.
18. Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem. 2003;278(7):4806-4812.
19. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007;67(3):946-950.
20. Jin SG, Wu X, Li AX, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 2011;39(12):5015-5024.
21. Rudenko A, Dawlaty MM, Seo J, et al. Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. Neuron. 2013;79(6):1109-1122.
22. Frycz BA, Murawa D, Borejsza-Wysocki M, et al. Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer. Biomed Pharmacother. 2014;68(2):209-212.
23. Jin SG, Jiang Y, Qiu R, et al. 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011;71(24):7360-7365.
24. Kudo Y, Tateishi K, Yamamoto K, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103(4):670-676.
25. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150(6):1135-1146.
26. Dzitoyeva S, Chen H, Manev H. Effect of aging on 5-hydroxymethylcytosine in brain mitochondria. Neurobiol Aging. 2012;33(12):2881-2891.
27. Chen H, Dzitoyeva S, Manev H. Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor Neurol Neurosci. 2012;30(3):237-245.
28. Nagy C, Suderman M, Yang J, et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol Psychiatry. Epub 2014 Mar 25.
29. Davies MN, Krause L, Bell JT, et al; UK Brain Expression Consortium. Hypermethylation in the ZBTB20 gene is associated with major depressive disorder. Genome Biol. 2014;15(4):R56.
30. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:334-339.
31. Dunner DL, Lipschitz A, Pitts CD, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther. 2005;27(12):1901-1911.
32. Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry. 2008;20(4):187-193.
33. Lee MS, Ahn YM, Chung S, Walton R, Raskin J, Kim MS. The effect of initial duloxetine dosing strategy on nausea in Korean patients with major depressive disorder. Psychiatry Investig. 2012;9(4):391-399.
34. Wang Y, Fang YR, Chen XS, et al. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients. Chin Med J (Engl). 2009;122(24):2956-2960.
35. Cheng TA, Wu JT, Chong MY, Williams P. Internal consistency and factor structure of the Chinese Health Questionnaire. Acta Psychiatr Scand. 1990;82(4):304-308.
36. Chong MY, Wilkinson G. Validation of 30- and 12-item versions of the Chinese Health Questionnaire (CHQ) in patients admitted for general health screening. Psychol Med. 1989;19(2):495-505.
37. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1-2):83-91.
38. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999;174:297-303.
39. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667.
40. Drinkwater RD, Blake TJ, Morley AA, Turner DR. Human lymphocytes aged in vivo have reduced levels of methylation in transcriptionally active and inactive DNA. Mutat Res. 1989;219(1):29-37.
41. Golbus J, Palella TD, Richardson BC. Quantitative changes in T cell DNA methylation occur during differentiation and ageing. Eur J Immunol. 1990;20(8):1869-1872.
42. Shimabukuro M, Sasaki T, Imamura A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res. 2007;41(12):1042-1046.
43. Shimabukuro M, Jinno Y, Fuke C, Okazaki Y. Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct. 2006;2:37.
44. Bromberg A, Levine J, Nemetz B, Belmaker RH, Agam G. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res. 2008;101(1-3):50-57.
45. Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71(3):255-264.
46. Kinoshita M, Numata S, Tajima A, et al. Aberrant DNA methylation of blood in schizophrenia by adjusting for estimated cellular proportions. Neuromolecular Med. Epub 2014 Jul 23.
47. Bromberg A, Bersudsky Y, Levine J, Agam G. Global leukocyte DNA methylation is not altered in euthymic bipolar patients. J Affect Disord. 2009;118(1-3):234-239.
48. Hillemacher T, Frieling H, Moskau S, et al. Global DNA methylation is influenced by smoking behaviour. Eur Neuropsychopharmacol. 2008;18(4):295-298.
49. Mehta D, Klengel T, Conneely KN, et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc Natl Acad Sci U S A. 2013;110(20):8302-8307.
50. Gryzinska M, Blaszczak E, Strachecka A, Jezewska-Witkowska G. Analysis of age-related global DNA methylation in chicken. Biochem Genet. 2013;51(7-8):554-563.
51. King GD, Rosene DL, Abraham CR. Promoter methylation and age-related downregulation of Klotho in rhesus monkey. Age (Dordr). 2012;34(6):1405-1419.
52. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal. 2013;18(15):1956-1971.
53. Sanchez-Roman I, Gómez A, Pérez I, et al. Effects of aging and methionine restriction applied at old age on ROS generation and oxidative damage in rat liver mitochondria. Biogerontology. 2012;13(4):399-411.
54. Ben-Avraham D, Muzumdar RH, Atzmon G. Epigenetic genome-wide association methylation in aging and longevity. Epigenomics. 2012;4(5):503-509.
55. Szulwach KE, Li X, Li Y, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci. 2011;14(12):1607-1616.
56. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129-1133.
57. Melas PA, Rogdaki M, Lennartsson A, et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol. 2012;15(5):669-679.
58. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011;19(3):109-124.
59. Jevtovic S, Karlovic D, Mihaljevic-Peles A, Seric V, Vrkic N, Jaksic N. Serum Brain-derived neurotrophirc factor (Bdnf): the severity and symptomatic dimensions of depression. Psychiatr Danub. 2011;23(4):363-369.
60. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord. 2003;77(3):255-260.